hat
OHPC te deja commercialisés anba Delalutin nan non komès pa Squibb, ki te apwouve pa Etazini (US) Manje ak Medikaman dwòg (FDA) nan 1956 ak retire nan maketing an 1999. [5] Li vann tou kòm Proluton toupatou nan Ewòp. [4] US FDA apwouve Makena soti nan KV famasetik (te rele yo kòm Gestiva) sou Fevriye 4, 2011 pou prevansyon de livrezon preterm nan fanm ki gen yon istwa de livrezon preterm, ki te pwovoke yon konfli prix.
eng
OHPC was previously marketed under the trade name Delalutin by Squibb, which was approved by the United States (U.S.) Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999.[5] It is also sold as Proluton throughout Europe.[4] The U.S. FDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy.